Prospective multicenter randomized placebo-controlled double-blind phase IV trial with two parallel treatment groups receiving either study product ( ORAL IMPACT ) or control supplement ( isocaloric isonitrogenous supplement -- IMPACT CONTROL ) for 7 days before liver resection for cancer .